GLEN ALLEN, Va. , May 10, 2013 /PRNewswire/ -- Star Scientific, Inc., (NASDAQ: STSI) today filed with the Securities Exchange Commission its Form 10-Q for the quarter ended March 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20130319/PH79245LOGO)
The company reported net sales of $2.5 million for the quarter ended March 31, 2013, compared with $1.1 million for the same period in 2012. The increase of 127% was attributable exclusively to increased Anatabloc® sales volume. The company also reported positive gross profits of $1.1 million for first-quarter 2013, compared to a gross profit of $0.4 million for the same period in 2012. The Company has reported increased net sales and positive gross profits in each of the last five quarters.
The net loss for first-quarter 2013 was $(8.2) million compared with a $(5.2) million net loss for the same period in 2012. The increased loss for the first quarter was primarily attributable to increases in sales and marketing costs, legal expenses, and research and development costs. Sales and marketing costs increased as the company expanded promotion of its Anatabloc® dietary supplement product. As reflected in the 10-Q Report, the Company expects that sales and marketing expenses will trend lower in the near-term as sales and marketing efforts related to Anatabloc® level out in 2013. Legal fees increased in connection with the previously reported ongoing investigations and class action lawsuits. As discussed in the 10-Q Report, the Company anticipates increased costs in this area in 2013.
Research and development costs increased in the first quarter as the Company continued to finalize reports on two clinical studies and continued work on its Rosacea clinical trial, which reached full enrollment during the first quarter 2013. As reported in the 10-Q Report, the Company expects that its R&D costs will trend lower in the near-term as work is finalized on the CRP and Hashimoto's autoimmune thyroiditis clinical studies.In February, Anatabloc® was selected as a recipient of the annual GNC Top Vendor Awards. Specifically, Anatabloc® was recognized by GNC as the Wellness Winner in the category of Best Product Innovation for 2012. More recently, Anatabloc® received registration approval from HFL Sports Science, a leading testing laboratory for banned substances. This qualification permits Star Scientific to use HFL's "Informed-Sport" and "Informed-Choice" trademarks on Registered Products, providing assurance that these products have been tested for substances prohibited in sport. Also, in January, the Company announced that John Isner, the top-ranked American player on the ATP World Tour, had agreed to act as the Company's second Brand Ambassador for Anatabloc®. PGA Tour Professional, Fred Couples, continues to serve in his role as the Company's first Anatabloc® Brand Ambassador. During the first quarter of 2013, the company expanded the Anatabloc® cosmetic products line with the introduction of Anatabloc® Revitalizing Facial Serum. Both Anatabloc® Facial Creme and Anatabloc® Facial Serum are available on the Company's product website, as well as on GNC's website. The company announced positive findings during the first quarter of 2013 in connection with an analysis of the initial results for all study subjects who completed the ASAP Human Thyroid health study. The company also reported positive results from a study conducted by researchers at the University of Virginia Medical School investigating the effects of anatabine in an animal model of idiopathic inflammatory bowel disease, ulcerative colitis.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV